Welcome to our dedicated page for Sotera Health Co news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health Co stock.
Sotera Health Co (SHC) delivers essential sterilization, lab testing, and advisory services ensuring safety across medical devices, pharmaceuticals, and food production. This page provides investors and industry professionals with timely updates on SHC's operational milestones, regulatory engagements, and strategic initiatives.
Access consolidated news on earnings reports, facility expansions, and technology innovations like gamma irradiation advancements. Track developments across SHC's Sterigenics, Nordion, and Nelson Labs divisions, including partnerships impacting global healthcare safety standards.
Bookmark this page for verified updates on SHC's compliance achievements, leadership changes, and industry contributions. Stay informed through carefully curated press releases and analysis-free reporting tailored for decision-makers in regulated industries.
Sotera Health (NASDAQ:SHC) reported strong Q2 2025 results with net revenues increasing 6.4% to $294 million. The company posted net income of $8 million ($0.03 per diluted share) and Adjusted EBITDA grew 9.8% to $151 million.
Key segment performance includes Sterigenics' revenue growth of 10.5% to $195 million, Nordion's increase of 2.9% to $42 million, while Nelson Labs saw a decline of 3.3% to $57 million. The company raised its full-year 2025 outlook, now expecting net revenue growth of 4.5% - 6.0% and Adjusted EBITDA growth of 6.0% - 7.5% on a constant currency basis.
The company maintains a strong balance sheet with $2.3 billion in total debt and $332 million in unrestricted cash, with an improved Net Leverage Ratio of 3.5x.
[ "Q2 net revenues increased 6.4% to $294 million", "Adjusted EBITDA grew 9.8% to $151 million with 160 basis points margin expansion", "Sterigenics segment showed strong 10.5% revenue growth to $195 million", "Company raised full-year 2025 outlook for revenue and Adjusted EBITDA", "Net Leverage Ratio improved to 3.5x from 3.7x", "No balance outstanding on $600 million revolving credit facility" ]Sotera Health (Nasdaq: SHC), a leading provider of sterilization solutions and lab testing services for the healthcare industry, has scheduled its second-quarter 2025 financial results release for August 8, 2025, before market open.
The company will host a conference call at 9:00 a.m. EDT to discuss results and operating highlights. Investors can participate via phone (US toll-free: 1-844-481-2916; International: 1-412-317-0709) or access the live webcast through the company's Investor Relations website. Conference materials will be available, and a webcast replay will be posted later that day.
[]Sotera Health (Nasdaq: SHC), a leading global provider of sterilization solutions and lab testing services for the healthcare industry, has scheduled its first-quarter 2025 financial results release for Thursday, May 1, 2025, before market opening.
The company will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss Q1 2025 results and operating highlights. Participants can join via phone (1-844-481-2916 US toll-free; 1-412-317-0709 international) or access the live webcast through the Investor Relations section of Sotera Health's website. Conference materials will be available, and a webcast replay will be accessible later that day.
Nelson Labs, a Sotera Health company, has launched Rapid Sterility Testing services at three laboratory sites across the United States and Europe. This innovative testing method reduces product sterility test results time from the traditional 14-day period to as little as 6 days, while maintaining compliance with USP <71> and <1223> standards.
The new testing solution uniquely supports both medical device and pharmaceutical products, expanding beyond the typical focus on biological components or short shelf-life products. The method employs quantitative data instrumentation to automate test results, reducing human error potential. This advancement enables faster product release while maintaining quality and safety standards.
Sotera Health (Nasdaq: SHC) reported its Q4 and full-year 2024 results, showing mixed performance. Full-year 2024 highlights include:
- Net revenues increased 4.9% to $1.10 billion
- Net income of $44 million ($0.16 per diluted share)
- Adjusted EBITDA grew 3.9% to $549 million
However, Q4 2024 showed some weakness:
- Net revenues decreased 6.5% to $290 million
- Net income dropped to $12 million ($0.04 per diluted share)
- Adjusted EBITDA declined 8.3% to $153 million
For 2025 outlook, the company projects:
- Net revenues growth of 4.0% - 6.0%
- Adjusted EBITDA growth of 4.5% - 6.5%
- Adjusted EPS range of $0.70 to $0.76
Sotera Health Company (Nasdaq: SHC), a leading global provider of sterilization solutions and lab testing services for the healthcare industry, has scheduled its fourth-quarter and full-year 2024 financial results release for Thursday, February 27, 2025, before market opening.
The company will host a conference call at 9:00 a.m. Eastern Time to discuss operating highlights and financial results. Participants can join by dialing 1-844-481-2916 (US) or 1-412-317-0709 (international locations). A live webcast and accompanying materials will be accessible through the company's Investor Relations website, with a replay available later that day.
Sotera Health (Nasdaq: SHC) presented at the 43rd Annual J.P. Morgan Healthcare Conference, where Chairman and CEO Michael B. Petras, Jr. provided a business update. The company, a leading provider of sterilization solutions and lab testing services for the healthcare industry, expects to report full-year revenues of approximately $1.1 billion for 2024, representing nearly 5% growth compared to 2023 and over 5% growth on a constant currency basis.
The company's management team, including CFO Jon Lyons and VP of Investor Relations Jason Peterson, are participating in investor meetings during the conference. A live webcast of the presentation is available on the company's website, with a replay to be archived. Full 2024 financial results and 2025 outlook will be reported on February 27, 2025.
Sotera Health Company (NASDAQ: SHC), a leading global provider of sterilization solutions, lab testing, and healthcare advisory services, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Chairman and CEO Michael B. Petras, Jr. will deliver a presentation on Tuesday, January 14, 2025, at 11:15 a.m. Eastern Time.
The company's senior leadership team, including CFO Jon Lyons and VP of Investor Relations Jason Peterson, will engage in investor meetings throughout the conference. Investors and interested parties can access a live webcast of the presentation through Sotera Health's Investor Relations website section under Presentations & Events. The presentation materials will be available for viewing, and a replay will be accessible within 48 hours after the conference concludes.
Sotera Health Company (Nasdaq: SHC) has appointed Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Petrella, who has been serving on the company's Board of Directors since 2020, will act as a key liaison among the Board, management, and shareholders.
The appointment leverages Petrella's decades of public company executive leadership and board experience, including his role as chairperson of Sotera Health's Audit Committee. Michael B. Petras, Jr., Sotera Health Chairman and CEO, highlighted Petrella's valuable experience, insight, and engagement since joining the Board.
FAQ
What is the current stock price of Sotera Health Co (SHC)?
What is the market cap of Sotera Health Co (SHC)?
